Navigation Links
China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010
Date:3/5/2010

ccrued expenses and other payables 2,853 19,472 19,269 Deferred revenue 5,135 35,049 18,351 Amounts due to related parties 384 2,621 -- Income tax payable 584 3,989 4,321 Total current liabilities 16,822 114,824 47,069 Deferred revenue 12,530 85,530 74,231 Other non-current liabilities 2,113 14,427 13,551 Deferred tax liabilities 414 2,827 4,017 Total liabilities 31,879 217,608 138,868 Commitments and contingencies Redeemable ordinary shares of China Cord Blood Services Corporation US$0.0001 par value, 14,614,140 shares issued and outstanding as of March 31, 2009 (redemption value of US$51,088,745 as of March 31, 2009) -- -- 386,577 EQUITY China Cord Blood Corporation shareholders' equity Ordinary shares US$0.0001 par value, 250,000,000 shares authorized, 43,237,100 shares and 66,182,726 shares issued and outstanding as of March 31, 2009 and December 31, 2009, respectively 7 45 34 Additional paid-in capital 102,233 697,834 140,745 Accumulated other comprehensive loss 2,055 14,023 (19,319) Retained earnings 10,425 71,161 44,082 Total China Cord Blood Corporation shareholders' equity 114,720 783,063 165,542 Noncontrolling interests 1,357 9,265 5,404 Total equity 116,077 792,328 170,946 Total liabilities, redeemable ordinary shares and equity 147,956 1,009,936 696,391 Exhibit 2 CHINA
'/>"/>
SOURCE China Cord Blood Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9
2. China Sky One Medical to Attend Rodman & Renshaw Annual China Investment Conference
3. China Baicaotang to Attend Rodman & Renshaw Annual China Investment Conference
4. China Medical Technologies Reports Third Fiscal Quarter Financial Results
5. Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing
6. China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor
7. China-Biotics, Inc. Inaugurated the Commercial Production of its New Production Facility
8. China Sky One Medical Confirms Continued Sale of Seven of Eight Products on the Ministry of Healths Warning List
9. China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results
10. China Medical Technologies to Participate Investor Conferences in March 2010
11. China Biologic Products Responds to Allegations on Financial Websites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 ... announced the addition of the "Global Biosimilars ... offering. The Global Biosimilars Market, 2015 ... the rapidly growing biosimilars market. With the blockbuster ... to minimize costs, biosimilars are being viewed as ...
(Date:7/29/2015)...  AmnioChor Inc., an early stage biotech startup based ... announce that the Musculoskeletal Transplant Foundation of ... their seed round of development of the proprietary AmnioCept™ ... AmnioChor,s technology allows cryopreservation of the amniotic ... living within those tissues. Amnion is a well-established source ...
(Date:7/29/2015)... SAN DIEGO , July 29, 2015  Pfenex ... quarter 2015 financial results will be released on Thursday, ... 8:30 am Eastern Time, Pfenex management will host a ... a business update.  A press release outlining the financial ... to the call. Please call 1-866-376-8058 (US) ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... The third ... of combination products , in particular, drug/device combinations. The current system received a ... the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( ...
Breaking Biology Technology:Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3
... SAN DIEGO, July 24, 2008 NuVasive, Inc.,(Nasdaq: ... on developing products for,minimally disruptive surgical treatments for ... previously announced acquisition of the Osteocel,biologics business from ... $35,million in cash, plus additional milestone-based contingent payments ...
... Calif., July 24 Abaxis, Inc.,(Nasdaq: ABAX ), a ... results for the first,fiscal quarter ended June 30, 2008., ... up 7% over last year,s comparable quarter. -- Total ... 127 units or 19% over last ...
... physicians, pulmonary and critical care clinicians, ... overuse of antibiotics, DURHAM, N.C., July 24 ... of the American Thoracic Society and,Society of Hospital ... physicians, and researchers are unanimous in their view ...
Cached Biology Technology:NuVasive Completes Acquisition of Osteocel Biologics Business 2NuVasive Completes Acquisition of Osteocel Biologics Business 3NuVasive Completes Acquisition of Osteocel Biologics Business 4NuVasive Completes Acquisition of Osteocel Biologics Business 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 8U.S. Clinicians Indicate a Strong Need for New Tools to Combat Sepsis 2U.S. Clinicians Indicate a Strong Need for New Tools to Combat Sepsis 3
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
(Date:7/7/2015)... 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... mobile commerce market announces a revised version of one of its ... will air on CNBC in New York , ... and San Francisco metro areas.    ... Wocket,s ability to replace all the cards in your wallet and ...
(Date:6/30/2015)... To bolster its efforts and commitment to fighting cyber fraud, ... of two new team members. Dimitri ... Raviv will act as head of strategic alliances. These ... the most secure solutions for the enterprise market. ... a provider of security and management products, which was acquired ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... Oct. 16, 2012  Today 23andMe, the leading personal ... as Vice President Communications, Neil Rothstein as Vice ... Strategic Alliances joining the company,s executive leadership team. ... Castro is responsible for the company,s corporate communications, ...
... MedNet Solutions, a global life sciences technology solutions ... & Data Corporation (SDC), a specialized Contract Research Organization ... services to the life sciences industry, are pleased to ... ™ EDC platform as their eClinical ...
... MOUNTAIN VIEW, Calif. and RAANANA, Israel, Oct. 23, ... ), the leading licensor of silicon intellectual property ... Ltd, a global supplier of embedded speech processing ... deliver enhanced speech processing solutions for smart devices, ...
Cached Biology News:23andMe Names Christine Castro, Neil Rothstein and Jonathan Ward to Leadership Positions 2Statistics & Data Corporation Selects MedNet Solutions As Strategic Technology Partner 2Statistics & Data Corporation Selects MedNet Solutions As Strategic Technology Partner 3CEVA, Rubidium Partner to Deliver Speech Processing Solutions based on the CEVA-TeakLite Family of DSPs 2CEVA, Rubidium Partner to Deliver Speech Processing Solutions based on the CEVA-TeakLite Family of DSPs 3
Mouse monoclonal antibody to RAD51L3 - RAD51-like 3 (S. cerevisiae)...
ACS Reagent Grade C 19 H 14 O 5 S Formula Weight: 354.38 PRODUCT SPECIFICATIONS Form: Rust/red crystalline powder Clarity of Solution: Passes test Visual Transition Interval: pH 6.8 - Yellow pH 8.2...
Mouse monoclonal [34B12] to Nop5p + Nop58p - Nucleolar Marker ( Abpromise for all tested applications)....
... Mouse Anti Nop1p/Fibrillarin (monoclonal) ... a nucleolar protein of bakers yeast, ... protein is essential for yeast viability ... The human homologue of Nop1p is ...
Biology Products: